Malabre Richard C 4
4 · Akebia Therapeutics, Inc. · Filed Jun 11, 2025
Insider Transaction Report
Form 4
Malabre Richard C
SVP, Chief Accounting Officer
Transactions
- Exercise/Conversion
Common Stock
2025-06-09$1.68/sh+15,000$25,200→ 281,914 total - Sale
Common Stock
2025-06-09$4.01/sh−15,000$60,150→ 266,914 total - Exercise/Conversion
Stock Option (Right to buy)
2025-06-09−15,000→ 321,000 totalExercise: $1.68Exp: 2034-01-31→ Common Stock (15,000 underlying)
Footnotes (4)
- [F1]This stock option exercise was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024.
- [F2]This sale was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024.
- [F3]The shares were sold at prices ranging from $4.00 to $4.03 and the price reported reflects the weighted average sale price.
- [F4]The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.